Title for MeetingAbstracts
Alphabetical listing of titles
Costs of New Drug Discovery versus a Restricted Formulary: is There a Conflict?
Costs of strategies for routine HIV counseling and testing of U.S. hospital patients.
Costs of treating AIDS patients in Africa.
Costs of treatment for HIV disease at a district hospital in Zambia.
Costs of treatment of patients with glaucoma or ocular hypertension in the Netherlands.
Costs to employers: the ignored perspective in technology assessment.
Costs, quality of life and disease severity in multiple sclerosis - a cross-sectional study in Sweden.
Cotrimoxazole (CMX) versus aerosolized pentamidine (AP) for primary prophylaxis of Pneumocystis carinii pneumonia (PCP).
Cotrimoxazole (T/S) for cerebral toxoplasmosis (CT) in AIDS.
Cotrimoxazole (TMP-SMX) desensitization using adjunctive steroid therapy in HIV/AIDS patients.
Cotrimoxazole (TMP-SMX) for primary prophylaxis of Toxoplasma encephalitis in advanced HIV patients. The MRC/ANRS International Coordinating Committee for the European Australian Alpha Trial.
Cotrimoxazole adherence and toxicity among persons with HIV in rural Uganda.
Cotrimoxazole and isoniazid preventive therapy in HIV-positive South African gold miners. preliminary results.
Cotrimoxazole as initial treatment and secondary prophylaxis of toxoplasmic encephalitis in AIDS patients.
Cotrimoxazole available at professional's and plwa association.
Cotrimoxazole prophylaxis for multiple opportunistic infections among HIV infected adults with active pulmonary tuberculosis.
Cotrimoxazole prophylaxis in HIV positive TB patients in a rural distirct of Malawi.
Cotrimoxazole prophylaxis of opportunistic infections in adults with HIV: a systematic review.
Cotrimoxazole treatment of toxoplasma encephalitis in AIDS patients.
Could a Vaccine against Group B Streptococcus (GBS) Protect against Vaginal Colonization?
Could HAART be safely discontinued in patients that initiated therapy without achieving actual recommended criteria of beginning of therapy?
Could HAART Influence the Effectiveness of HCV Treatment in HIV-Infected Patients?
COULD MULTIPLE MODES OF BINDING OF A POTENT NNRTI TMC125-R165335 EXPLAIN ITS POTENCY AGAINST COMMON DRUG-RESISTANT MUTANTS?
Could Multiple Modes of Binding of a Potent NNRTI TMC125-R165335 Explain Its Potency Against Common Drug-resistant Mutants?
Could PBMC HIV Proviral DNA Genotypic Testing be used as a Surrogate Marker in Low-Level Replicating Patients?
Could splenectomy improve survival in HIV patients? A study of patients with HIV-related thrombocytopenia (HIV-rel TP).
Could the clinical practice guidelines (CPG) be a method for establishing quality indicators in acute myocardial infarct (AMI)?
Could the clinical practice guidelines (CPG) be a method for establishing quality indicators? The stroke experience.
Could the REACH model be the panacea to female genital cutting (FGC) and the associated risks of HIV infection?
Could the use of complementary therapies influence the adherence to HAART regimen?